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Sepsis-related mortality roughly doubles when acute kidney injury (AKI) occurs and 
end-stage renal disease is more common in sepsis-associated AKI survivors. So 
far, no licensed treatment for the prevention of AKI is available, however the data on 
alkaline phosphatase (AP) is promising and might change this. Sepsis-associated AKI is 
believed to be the result of inflammation and hypoxia combined. Systemic inflammation 
started by recognition of ‘pathogen-associated molecular patterns’ (PAMPs) such as 
lipopolysaccharide (LPS) which binds to Toll-like receptor 4 and leads to the production 
of inflammatory mediators. Due to this inflammatory process renal microcirculation gets 
impaired leading to hypoxia resulting in cell damage or cell death. In the process of cell 
damage so called ‘danger-associated molecular patterns’ (DAMPs) are released resulting 
in a sustained inflammatory effect. Apart from the systemic inflammation DAMPs and 
PAMPs also interact with receptors in the proximal tubule of the kidney causing a local 
inflammatory response leading to leukocyte infiltration and tubular lesions, combined 
with renal cell apoptosis and ultimately to AKI. In the longer-term, inflammation-mediated 
inadequate repair mechanism may lead to fibrosis and development of chronic kidney 
disease. AP is an endogenous enzyme that dephosphorylates and thereby detoxifies 
several compounds, including LPS. A small phase 2 clinical trial in sepsis patients showed 
that urinary excretion of tubular injury markers was attenuated and creatinine clearance 
improved in sepsis patients treated with AP. This renal protective effect was confirmed 
in a second small clinical phase 2 trial in sepsis patients with AKI. Subsequently, a large 
trial in sepsis patients with AKI was conducted using a human recombinant AP. In 301 
patients no improvement of kidney function within 7 days after enrolment was observed, 
but kidney function was significantly better on day 21 and day 28 and all-cause 28-day 
mortality was significantly lower (14.4% in AP group versus 26.7% in the placebo 
group). Possible explanations of this lack of short-term kidney function improvement are 
discussed and potential effects of AP on renal repair mechanisms, including inflammation-
mediated induction of fibrosis, that may explain the beneficial longer-term effects of AP 
are proposed.
Keywords: acute kidney injury, recombinant alkaline phosphatase, sepsis, septic shock, sepsis-associated acute 
kidney injury, chronic kidney disease, renal function, fibrosis
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BACKGROUND
Acute kidney injury (AKI) is defined by an increase in serum 
creatinine or a decrease in urine output (Kidney Disease: 
Improving Global Outcomes (KDIGO) Acute Kidney Injury 
Work Group, 2012), as representatives of loss of kidney function. 
The incidence of AKI in the intensive care unit (ICU) is up to 
60% (Hoste et al., 2015) with sepsis as the most common cause of 
AKI, accounting for over 40% of cases (Angus et al., 2001). Sepsis-
related morbidity, mortality, and costs of treatment represent 
a persistently high burden (Kumar et al., 2011; Fleischmann 
et al., 2016). Approximately half of sepsis patients need to be 
admitted to the ICU due to reduced or complete loss of function 
of one or multiple vital organs (Angus et al., 2001). Sepsis-related 
mortality is significant as one in three patients dies, and this 
roughly doubles when loss of kidney function occurs (Hoste 
et al., 2015). Patients that survive an episode of sepsis-associated 
AKI (SA-AKI) demonstrate an increased risk of developing end-
stage renal disease later in life (Chawla et al., 2011).
SA-AKI was initially thought to result from a deterioration 
in macrohemodynamics, resulting in reduced kidney perfusion, 
ischemia, and subsequent tubulus necrosis (Uchino et al., 2005). 
However, AKI may occur during a state of increased renal blood 
flow, and histological findings do not show widespread tubular 
necrosis compatible with ischemia but instead a heterogeneous 
and patchy pattern of tubular cell injury (Langenberg et al., 2005; 
Langenberg et al., 2006). It has become increasingly clear that 
the pathogenesis of SA-AKI is a complex and multifactorial 
syndrome consisting of damage due to inflammatory processes, 
ischemic damage due to altered microcirculation, and impaired 
renal bioenergetics (Gomez et al., 2014; Bellomo et al., 2017).
The inflammatory response to a pathogen starts with the 
recognition of distinct “pathogen-associated molecular patterns” 
(PAMPs), by the innate immune system (Kawai and Akira, 2007). 
Through different signaling pathways, e.g., Toll-like receptors 
(TLRs), an inflammatory response is triggered causing the release 
of several inflammatory mediators. Subsequent cellular injury 
may lead to the release of adenosine triphosphate (ATP) (Eltzschig 
et al., 2012), that in turn acts as a “danger-associated molecular 
pattern” (DAMP). While the inflammatory response is essential 
in fighting an infection, during sepsis, this inflammatory response 
becomes unbalanced causing adverse and harmful effects (Chen 
and Nuñez, 2010; Gustot, 2011). Lipopolysaccharide (LPS) 
is part of the outer cell membrane of Gram-negative bacteria 
(Cohen, 2002) and is the most extensively studied PAMP. LPS 
binds to Toll-like receptor 4 (TLR4) which initiates the systemic 
inflammatory response (Peters et al., 2014a). Intriguingly, not 
only immune cells but also tubular cells express TLRs. Because 
LPS, among other PAMPs, DAMPs and inflammatory mediators, 
is filtered in the glomeruli, it can directly bind to TLR4 in the 
proximal tubule of the kidney (El-Achkar et al., 2006), within 
minutes after infusion (Good et al., 2009) causing activation of 
the complement system, coagulatory pathways, as well as release 
of cellular ATP, cytokines, and chemokines, transmigration of 
leucocytes, production of reactive oxygen species (ROS), and 
reactive nitrogen species (RNS) in the kidney (Peters et al., 
2014a). Acute tubular lesions, apoptosis, and leucocyte infiltrates 
ultimately cause renal function impairment; AKI has occurred 
(Peters et al., 2014a).
Once the acute phase has passed, a phase of repair and 
regeneration often allows reversal of loss of kidney function 
to a great extent (Rabb et al., 2016). Some parts of the immune 
system that caused the initial damage play a role in the organ 
recovery as well; for example, the role of macrophages changes 
from proinflammatory to proregeneration (Jang and Rabb, 
2014), also mediated through TLR4 receptor activation. 
When TLR4 on macrophages or interstitial dendritic cells 
are activated, it stimulates the production of interleukin-22 
(IL-22), accelerating the reepithelialization by the tubular 
epithelial cells that have survived the first phase of acute injury 
(Kulkarni et al., 2014). An alternative response following organ 
damage is the formation of fibrosis; a deviant form of healing. 
Fibrosis originates from the production of myofibroblast cells 
and overproduction of extra cellular matrix by fibroblasts and 
mesangial cells (Anders and Schaefer, 2014). Unfortunately, 
these cells can also be activated by PAMPs and DAMPs via 
their TLRs. TLR activation by DAMPs on fibroblasts and 
mesangial cells leads to increased excretion of extracellular 
matrix, increased proliferation, and increased transition into 
myofibroblast cells (Anders and Schaefer, 2014).
In conclusion PAMPs and DAMPs exert proinflammatory 
effects systemically, but also locally in the kidney, leading to 
undesirable consequences. Nevertheless, the TLR-pathway 
also plays a role in the maladaptive regeneration following 
this initial response, leading to a profibrotic effect which is 
undesirable during healing. The finding that TLR activation 
plays a role in the initiation of regenerative effects, implicates 
that an immunomodulating treatment against sepsis which 
might interfere with PAMP/DAMP-TLR activation pathways is 
highly complex.
Up to now, no drug is licensed for the prevention and 
treatment of SA-AKI. Currently, the clinical focus is mainly 
on supportive care, such as renal replacement therapy, and 
secondary prevention to prevent further harm. Due to the much 
higher mortality of sepsis when accompanied by AKI, and the 
long-term impact on renal function after surviving the disease, 
the need for a treatment of SA-AKI is paramount.
ALKALINE PHOSPHATASE
Alkaline phosphatase (AP) is an endogenous occurring 
detoxifying enzyme which is present throughout the body 
in four different iso-enzymes: germ-cell AP, intestinal AP, 
placental AP, and a non-tissue-specific form which is mostly 
derived from the kidneys, liver, and skeleton (Millán, 2006). As 
described above, for example the DAMP endotoxin contains two 
phosphate groups and removal of one of the phosphate groups 
by a dephosphorylating molecule results in a nontoxic lipid A 
moiety (Bentala et al., 2002). The dephosphorylated endotoxin 
can still bind to TLR4 but fails to activate it, and thus exerts 
TLR4-antagonistic properties. AP is able to dephosphorylate 
endotoxin (Poelstra et al., 1997). The presence of free phosphate, 
using enzymatic in vitro assays and in vivo histochemical 
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analysis, revealing phosphatase activity present at the tubular 
brush borders (Poelstra et al., 1997; Bentala et al., 2002; Verweij 
et al., 2004) confirms this ability of AP and in accordance 
protects animals in Gram-negative Escherichia coli sepsis 
models, whereas not affecting survival when exposed to Gram-
positive bacterium Staphylococcus aureus (Poelstra et al., 1997). 
By its dephosphorylating ability, AP is able to detoxify not only 
endotoxin, but various compounds. The widespread presence 
of AP indicates a wide range of functions during sickness and 
health. AP measured in serum is currently used as diagnostic 
tool in liver disease (Siddique and Kowdley, 2012), bone diseases 
(Ross et al., 2000), and testicular cancer (Neumann et al., 
2011). However, AP might also play an important role in the 
treatment of the critically ill. Its dephosphorylating capacity could 
counteract the undesirable cascades of molecules including 
PAMPs (Koyama et al., 2002) and DAMPs (Picher et al., 2003) 
during sepsis. The lipid A part of the outer membrane of LPS 
contains two phosphate groups, of which one that can be 
dephosphorylated by AP (Koyama et  al., 2002; Peters et al., 
2014a). With its capability to detoxify LPS, AP was initially 
thought of to represent a promising antisepsis drug.
In addition to the detoxifying effect of AP on LPS, a 
potential other mode of action of AP during sepsis is the 
dephosphorylation of ATP. ATP is, under normal circumstances, 
located intracellular where it has an energy providing function. 
Cellular stress, caused by, e.g., hypoxia or inflammation, may 
cause ATP to be released into the extracellular space where 
it acts as a DAMP potentiating the inflammatory process 
(Bours et al., 2006). AP catalyses the dephosphorylation 
of extracellular ATP to adenosine diphosphate, adenosine 
monophosphate, and finally to adenosine (Peters et al., 2014a). 
Binding to its receptors in the nephron, adenosine may play 
a role in the regulation of renal blood flow by influencing 
vascular tone as well as regulating the glomerular filtration 
rate through tubuloglomerular feedback and renine release 
(Vallon et al., 2006). In addition, the adenosine receptors 
in the nephron are also present on immune cells (Ramakers 
et al., 2011) and when activated, induce protective effects 
on tissue by an anti-inflammatory response (Bauerle et al., 
2011). Several other interventions related to the LPS–TLR4 
pathway have been tested, including LPS antibodies and TLR4 
antagonists. For example a large clinical study investigating the 
effects of a synthetic lipid A antagonist that blocks endotoxin-
binding to the MD2–TLR4 receptor on mortality did not show 
a clinical benefit (Opal et al., 2013). Of interest, patients with 
Gram-positive bacterial infections appeared to do worse in the 
treatment group compared to placebo and it was suggested 
that comedication interfering with TLR4 signaling may have 
influenced the results. Of interest, the described unspecific 
effects of AP, removing phosphate groups from different 
compounds, may account for its therapeutic efficacy compared 
to much more specific interventions.
Preclinical Data
Administration of exogenous AP has been extensively investigated 
in animal models, showing the capacity to significantly attenuate 
the plasma tumor necrosis factor-α (TNF-α) levels (van Veen 
et al., 2005), plasma IL-6 levels (van Veen et al., 2005), serum 
nitric oxide (NO) levels (Verweij et al., 2004), associated with 
less pronounced organ dysfunction (van Veen et al., 2005), and a 
significant increase in survival in various sepsis models (Bentala 
et al., 2002; Beumer et al., 2003; Verweij et al., 2004; Su et al., 
2006) (see Table 1). A deeper analysis of the preclinical data has 
previously been published by Peters et al., (2013).
Clinical Data
Bovine intestinal AP (biAP) was administered to 67 
healthy volunteers in various doses to determine safety and 
pharmacokinetics (Pickkers et al., 2009). A proportional and 
linear response to the different loading doses was found. 
Continuous infusion of biAP for 24–72 h showed a stable level 
throughout the period of infusion and was used to determine 
the elimination half-life of approximately 8 h.
Following the efficacy studies in animals and the safety and 
kinetics studies in healthy volunteers, a small phase 2 clinical 
trial in 36 suspected or proven Gram-negative sepsis patients 
(with or without AKI) was conducted (Heemskerk et al., 
2009). Patients received a loading dose of 67.5U/kg biAP and a 
continuous infusion of 132.5U/kg/24 h biAP for 24 h. No safety 
concerns emerged in this critically ill population. Overall, 
no signal that bovine AP affected the systemic inflammatory 
response or clinical outcome was observed in this small phase 
2 trial. However, in patients treated with biAP an improvement 
of endogenous creatinine clearance (ECC) was observed, 
while renal function further deteriorated in patients treated 
with placebo. Of interest, the urinary excretion of tubular 
injury markers was less pronounced in the biAP-treated group 
compared to placebo. When looking at the subgroup of patients 
who had AKI at enrolment, the trial suggested better survival 
rates for the biAP-treated group compared to the placebo 
group  (27% versus 60% respectively, p = 0.21), but obviously 
the trial was grossly underpowered to demonstrate clinically 
relevant effects.
In view of the renal effects of biAP, a second small phase 2 trial 
was designed to focus specifically on sepsis patients with signs 
of early AKI. This second phase 2 trial also included 36 patients 
with proven or suspected Gram-negative sepsis or shock and as 
an additional inclusion criteria proven AKI (as defined by AKIN 
criteria or rise in serum creatinine to >150µmol/l in the last 
48 hours). The patients were treated with the same loading dose 
of biAP of 67.5U/kg followed by continuous infusion of biAP 
of 132.5U/kg/24 for 48 h. The renal protective effects of biAP 
were confirmed, as patients treated with biAP demonstrated a 
more pronounced improvement of renal function compared to 
patients treated with placebo (Pickkers et al., 2012).
Following these two small phase 2 trials it was decided to 
develop a human recombinant AP, as biAP retrieved from calf 
intestine has various drawbacks, including the (minimal) risk 
of bovine spongiform encephalopathy and occurrence of an 
undesirable immune response. In the development of the human 
recombinant form of AP (recAP), it was decided to combine the 
biologically active intestinal AP and the very stable placental AP. 
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TABLE 1 | Overview of alkaline phosphatase related (pre)clinical research.
AP related effects
Study Species Model Treatment Sample size Outcome
Yao et al. 
(1994)
Rats IV LPS injection Pretreatment with 
monophosphoryl lipid A (MLA; a 
dephosphorylated form of lipid A 
in LPS) 5 mg/kg for 24 
NR LPS: 89% mortality at 48 following administration
LPS + MLA: 0% mortality at 48 following administration and inhibited all of the manifestations of 
disseminated intravascular coagulation produced by endotoxin.
Poelstra et al. 
(1997)
Rats Intraperitoneal E. coli/
Staphylococcus aureus 
injection
Levamisole (inhibitor of intestinal 
AP) 50 mg/kg BW
42 Inhibition of endogenous AP by levamisole significantly reduced survival of rats intraperitoneally injected with 
E. coli bacteria.
Preclinical 
Study Species Model Treatment Sample size Outcome
Bentala et al. 
(2002)
Mice Intraperitoneal 
D-galactosamine + 
LPS injection 
IV bolus injection of 0.1 U 
placental AP
7 Survival rate: 100% (treated) vs 57% (untreated), P = NR
Koyama et al. 
(2002)
Rats Oral LPS administration Oral administration of 40 mg/kg 
BW l-phenylalanine (inhibitor of 
intestinal AP)
3 Serum LPS levels: 180 pg/ml (treated) vs 340 pg/ml (untreated), P < 0.05
Beumer et al. 
(2003)
Mice Intraperitoneal E. coli 
injection
IV bolus injection of 1.5 U biAP 5 Survival rate: 80% (treated) vs 20% (untreated), P < 0.01
Body temperature decreased to: 36.2 ± 0.7°C (treated) vs 34.2 ± 0.8°C (untreated), P < 0.05
Beumer et al. 
(2003)
Piglets IV LPS injection IV injection of 2,500 U biAP 1–3 per group Platelet counts decreased to: 41 ± 4 × 109/L (treated) vs 19 ± 1 × 109/L (untreated), P < 0.05
Verweij et al. 
(2004)
Mice Intraperitoneal E. coli 
injection
IV bolus injection of 1.5 U 
placental AP
14 Survival rate: 100% (treated) vs 58% (untreated) P < 0.01
Serum NO levels increased to: 75 μmol/L (E. coli, untreated) vs 16 μmol/L [control (no E. coli)], P < 0.01; 
39 μmol/L (E. coli, treated) vs 16 μmol/L [control (no E. coli)], P = NS.
van Veen 
et al. (2005)
Mice Cecal ligation and 
puncture
IV bolus injection of 0.15 U/g BW 
biAP
8 Significant reduced systemic inflammatory response defined as lower peak-plasma levels of TNF-α, IL-6 
an MCP-1 and significant signs of reduced injury to liver an lung defined as reduced serum AST/ALT levels 
and reduced MPO activity in the lung (myeloperoxidase, indicator for tissue inflammation). No significant 
improvement of survival was shown.
Su et al. 
(2006)
Sheep Intraperitoneal feces 
injection
IV bolus injection of 60 U/kg BW 
Intestinal AP
followed by continuous infusion of 
20 U/kg/h for 15 h
NR Median survival significantly improved following AP administration (23.3 vs 17, p < 0.05).
Plasma IL-6 level: 0.16 AU (treated) vs 0.20 AU (untreated), P < 0.05
Gas exchange (PaO2:FiO2 ratio) decreased to: 320 mm Hg (treated) vs 50 mm Hg (untreated), P < 0.05.
Peters et al. 
(2015)
Rats IV LPS injection IV bolus injection of 1000 U/kg BW 
human recombinant AP (recAP)
18 In vivo: LPS administration significantly prolonged FITC-sinistrin half-life (as a measure of glomerular filtration 
fraction), which was prevented by recAP coadministration.
RecAP prevented LPS-induced increase in proximal tubule injury markers.
In vitro: LPS-induced production of TNF-α, IL-6, and IL-8 was significantly attenuated by recAP. This effect 
was linked to dephosphorylation, as enzymatically inactive recAP had no effect on LPS-induced cytokine 
production. RecAP-mediated protection resulted in increased adenosine levels through dephosphorylation 
of LPS-induced extracellular ATP and ADP. Also, recAP attenuated LPS-induced increased expression of 
adenosine A2A receptor. 
Peters et al. 
(2016)
Rats Renal ischemia (30 
min) and reperfusion
IV infusion of 1,000 U/kg recAP 18 RecAP prevented I/R-induced alterations of renal hemodynamics immediately following reperfusion. RecAP 
treatment prevented I/R injury-induced renal inflammation.
Peters et al. 
(2016)
Rats LPS infusion (30 min) IV infusion of 1,000 U/kg recAP 18 LPS-induced systemic hemodynamic instability and impaired renal oxygenation was not influenced by 
recAP. RecAP attenuated biomarkers of renal inflammation and damage during endotoxin-induced shock.
(Continued)
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TABLE 1 | Continued
Clinical
Study Design Treatment Sample size Outcome
Heemskerk 
et al. (2009)
Multicenter double-blind, 
randomized, placebo-controlled 
phase IIa study
Bovine AP: IV bolus injection 
of 67.5 U/kg BW, followed by 
continuous infusion of 132.5 U/kg 
or placebo
36 In sepsis patients, median creatinine clearance [IQR] increased from 54 [24–84] to 76 [25–101] ml/min in the 
24 h after AP treatment, while it decreased from 80 [77–91] to 59 [45–59] in the placebo group, P < 0.05.
Pathophysiology of NO production and subsequent renal damage were assessed in a subgroup of 15 
patients. A 42-fold induction (vs. healthy subjects) in renal inducible NO synthase expression was reduced 
by 80 ± 5% after AP treatment. In AP-treated patients, the increase in cumulative urinary NO metabolite 
excretion was attenuated, whereas the opposite occurred after placebo. Reduced excretion of NO 
metabolites correlated with the proximal tubule injury marker glutathione S-transferase A1-1 in urine, which 
decreased by 70 [50–80]% in AP-treated patients compared with an increase by 200 [45–525]% in placebo-
treated patients.
Pickkers et al. 
(2012)
International double-blind, 
randomized, placebo-controlled 
phase IIa study
Bovine AP: IV bolus injection 
of 67.5 U/kg BW, followed 
by continuous infusion of 
132.5 U/kg/24h or placebo
36 In patients with SA-AKI, there was a significant (P = 0.02) difference in favor of AP treatment relative to 
controls for the primary outcome variable (progress in renal function variables (ECC, requirement and 
duration of renal replacement therapy) in 28 days). The improvement of ECC was significantly more 
pronounced in the treated group relative to placebo (from 50 ± 27 to 108 ± 73 ml/min) for the AP group; 
and from 40 ± 37 to 65 ± 30 ml/min for placebo; P = 0.01). Reductions in RRT requirement and duration 
were not significantly different between groups. The results in renal parameters were supported by 
significantly more pronounced reductions in the systemic markers C-reactive protein, IL-6, LPS-binding 
protein, and in the urinary excretion of KIM-1 and IL-18 in AP-treated patients relative to placebo. 
Pickkers et al. 
(2018)
International double-blind, 
randomized, placebo-controlled, 
dose-finding, adaptive phase IIa/b 
study
Human recombinant AP: 0.4 mg/kg 
(n  =  31),
0.8 mg/kg (n  =  32), or
1.6 mg/kg (n  =  111)
or placebo (n  =  116), once daily 
for 3 days
301 In patients with SA-AKI, from day 1 to day 7, median ECC increased with 37.4 [26–65.4] and 26 [35.9–61.9] 
ml/min in recAP and placebo, P = NS. Improvement in ECC over 28 days was significantly better in the 
recAP group compared to placebo (P = 0.04). Day 28 and day 90 mortality for recAP and placebo were 
14.4 and 26.7% (P = 0.02) and 17.1 and 29.1% (P = 0.03), respectively. 
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The resultant biologically active and long half-life recAP was 
produced for the upcoming large phase 2 clinical trial (Figure 1)
(Kiffer-Moreira et al., 2014).
The STOP-AKI trial was the first international, randomized, 
double-blind, placebo-controlled trial evaluating the effect of 
recAP on kidney function during SA-AKI and was designed to 
determine the optimal dose of recAP and to evaluate adverse 
events and efficacy (Pickkers et al., 2018). The trail enrolled 
301 patients in 11 countries who were diagnosed with SA-AKI. 
Following blinded interim analysis, the 1.6 mg/kg recAP (once 
daily on three consecutive days) group was favored to continue 
the study. The primary endpoint focused on the mechanism of 
action, an improvement of ECC within 7 days, powered to detect 
a difference of 19 ml/min in ECC over the first week following 
enrolment. Unfortunately, despite randomization, the recAP 
treatment group had a somewhat lower median [interquartile 
range (IQR)] ECC on day 1 of 26.0 [8.8–59.5] ml/min, compared 
to the placebo group (35.9 [12.2–82.9] ml/min). Seven days later 
ECC increased to 65.4 [26.7–115.4] ml/min in the recAP group, 
compared to 61.9 [22.7–115.2] ml/min in the placebo group, a 
difference that was not statistically significant. Nevertheless, ECC 
improvement from enrolment up to day 28 was significantly 
better in the recAP group compared to the placebo group and this 
treatment effect was caused by the difference that occurred on day 
21 (mean difference, 16.3 ml/min [95% confidence interval (CI), 
3.1 to 29.5]; p = 0.02), and day 28 (mean difference, 18.5 ml/min 
[95%CI, 5.3 to 31.7]; p = 0.006). Furthermore, all-cause mortality 
at day 28 was 14.4% for the recAP group versus 26.7% for the 
placebo group (p = 0.02), this difference persisted until the end of 
follow-up at day 90 (17.1% for the recAP group versus 29.1% for 
the placebo group; p = 0.03). Post hoc exploratory analyses were 
performed to test the robustness of the observed survival benefit 
in the recAP group. Forward stepwise multivariable analysis 
found 15 covariates that are associated with outcome. Treatment 
with recAP, disease severity score, baseline ECC, and time to 
recAP treatment emerged as significant independent prognostic 
factors for survival. The short-term renal outcome discrepancy 
could be due to a number of factors. First, the estimated kidney 
function based on ECC is known to be imprecise. Creatinine-
based calculations to estimate kidney function are often used 
but with recognized limitations in the acute phase of critical 
illness, as serum creatinine is a late and insensitive marker of 
kidney function. However, a more precise marker of kidney 
function is currently not available. Additionally, the recAP-
treated group of the STOP-AKI trial had a slightly more impaired 
kidney function upon study initiation, which could account 
for a less pronounced improvement of ECC in the first week. 
Analysis of the short-term renal function improvement did, 
however,  not take into consideration the 8–10 ml/min baseline 
kidney function disadvantage in the recAP-treated group. 
Exploratory post hoc analysis of the STOP-AKI trial found that 
baseline ECC strongly correlated with renal improvement, 
suggesting an underestimation of improved kidney function in 
the recAP-treated group. Considering that the initial degree of 
kidney dysfunction is prognostic for survival, the significance of 
the difference in mortality in favor of the recAP-treated group, 
FIGURE 1 | Schematic overview of the mechanism of action of recombinant AP. AP is able to dephosphorylate different compounds and thereby detoxifies 
these compounds. Left part of figure: Circulating endotoxin (LPS) in sepsis patients is filtered in the kidneys and recognized by tubular epithelial cells that express 
pathogen pattern receptors, such as TLR4. It is now recognized that the subsequent renal inflammatory response can be detrimental to kidney function. LPS 
contains two phosphate groups. RecAP is able to remove a phosphate group from LPS, after which the LPS can still bind to the TLR4, but does no longer induce 
the inflammatory cascade. Even more so, dephosphorylated LPS acts as a TLR4 antagonist for intact LPS containing two phosphate groups. During sepsis, ATP 
is released from cells. Extracellular ATP exerts proinflammatory effects. In addition to LPS as a PAMP, ATP acts as a DAMP. Dephosphorylation of ATP by recAP 
results in the formation of ADP, AMP, and eventually adenosine. Adenosine exerts anti-inflammatory and tissue-protective effects. Right part of figure: Apart from 
these mechanisms during acute inflammation, also kidney (maladaptive) kidney tissue repair mechanisms are, at least partly, mediated via inflammatory mediators 
and TLRs. We hypothesize that also in this maladaptive regeneration phase of AKI, which could lead to the formation of fibrosis, recAP could play a therapeutic 
role. Dephosphorylation of different PAMPs and DAMPs by recAP could influence the DAMP/PAMP–receptor interaction which results in to less fibrosis formation 
and therefore positively influence longer-term renal function. We propose that future research will look into this mechanism of recAP in relation to prevention of 
maladaptive repair mechanisms and fibrosis.
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against this baseline ECC–mortality association, is strengthened 
by the poorer initial kidney function in this group. The increased 
survival of the recAP-treated patients might also partly explain 
the overall moderate improvement of kidney function. It could 
be argued that, due to recAP treatment, a group of critically 
ill patients survived SA-AKI that would otherwise have died. 
Survival of these severely ill patients might have brought down the 
average kidney function of the recAP-treated group. Conceivably, 
the 7-day period may have been too short to detect an effect of 
recAP on kidney function in the larger trial, as differences in 
creatinine clearance only became clear after 3 and 4 weeks. One 
might argue that recAP might resolve AKI to a greater extent, 
compared to influencing the development of AKI. In other words, 
it appears possible that recAP may modulate the sustained low-
grade renal inflammatory response that is associated with the 
formation of fibrosis and longer-term impaired renal function to 
a greater extent than interfering in the acute processes associated 
with the development of AKI in the early phase. This possibility is 
of interest, but currently, there is no preclinical research available 
into this putative mechanism of action of AP.
DISCUSSION
Administration of exogenous AP was initially thought to be of 
potential therapeutic use as a general antisepsis drug aimed to 
modulate the systemic inflammatory response by detoxifying 
PAMPs (such as LPS) and DAMPs (such as extracellular ATP) by 
dephosphorylation. However, in two small clinical trials it emerged 
that the therapeutic efficacy on the kidney was most pronounced. 
Subsequently, the focus shifted toward a specific treatment for 
SA-AKI. In the large phase 2 trial applying human recombinant AP, 
no safety issues emerged, but the compound failed to demonstrate a 
statistically significant difference in primary endpoint: improvement 
of short-term renal function. Nevertheless, longer-term renal 
function was beneficially influenced by recAP and, even more 
impressive, survival was significantly better in patients treated with 
recAP compared to patients receiving placebo. Following additional 
analyses, it appears that this survival benefit is robust. As impaired 
kidney function leads to a series of nonrenal, but potentially life 
threatening consequences during the later course, e.g., fluid 
overload causing cardiovascular failure, prolonged weaning from 
mechanical ventilation, and impaired nutrient absorption as well 
as drug toxicity due to dosing difficulties (Elapavaluru and Kellum, 
2007), the longer-term beneficial effects of recAP on the kidneys 
may account for the observed survival benefit.
Mechanism of Action
So far, research related to the therapeutic efficacy of AP has 
focused on attenuation of the inflammatory response elicited 
by PAMPs and DAMPs. Based on laboratory and animal data, 
modulation of these pathways by AP appears to account for the 
observed beneficial effects of AP administration. Indeed, it seems 
plausible that these mechanisms of action are also of relevance 
for the therapeutic efficacy observed in patients. Nevertheless, 
the observation in the recent phase 2 trial that treatment with 
recAP results in improvement of renal function, which is most 
pronounced 3–4 weeks following enrolment, suggests that recAP 
may also affect renal processes that occur in this subacute phase. As 
eluded to earlier, following the initial insult, repair processes in the 
kidney also involve TLR pathways and inadequate repair processes 
leading to fibrosis are also at least partly mediated through these 
pathways (Anders and Schaefer, 2014). It is currently unknown 
whether or not AP is able to interfere in these pathways. If so, 
recAP-mediated stimulation of regeneration may account for the 
protective effects observed 21 and 28 days following enrolment, in 
addition to modulation of acute inflammation-induced damage.
A possible therapeutic effect of recAP on sepsis may lead 
to general improvements, that may indirectly lead to a better 
renal function. However, in the STOP-AKI trial the course of 
organ dysfunction of different organs was followed and organ 
improvement was most pronounced in the kidneys, suggesting 
that a renal effect may be present. The positive effects of recAP 
observed on kidney function after 3 and 4 weeks and on 
survival in the STOP-AKI trial are undoubtedly promising, and 
arguably even more important than just early improvement in 
kidney function. The long half-life of the recombinant AP may 
be of importance of the observed longer-term renal effects. 
Consequently, a prospective phase III trial is needed to confirm 
these results. Apart from survival, if enhanced kidney function 
turns out to be a sustained effect, this could lead to a decrease in 
the occurrence of end-stage renal disease following AKI.
Several other issues are of interest to consider. The clinical 
trials in which the clinical efficacy of AP was investigated were 
performed in sepsis patients with early AKI. Starting treatment 
earlier during the course of the illness, e.g., when AKI is not 
yet diagnosed, could potentially maximize the protective effect 
of AP and prevent the occurring of damage. In view of the 
profound effect on survival, lack of safety concerns related to 
the administration of AP that would argue against a more broad 
indication, this would be of interest. Similarly, as AP was shown 
to exert renal protective effects in other preclinical models of AKI 
[e.g., ischemia–reperfusion (Peters et al., 2016), or cisplatinum-
induced (Peters et al., 2014b) AKI], future clinical trials in other 
patient groups would be of interest as well.
In summary, AP is a detoxifying enzyme that exerts effects 
by dephosphorylation of various compounds. Exogenous 
administration of AP exerts kidney protective effects in various 
animal models of sepsis. Two small phase 2 trials with bovine 
AP showed beneficial renal effects. A recently completed large 
phase 2 trial applying a human recombinant AP failed to 
show a benefit on creatinine clearance during the first 7 days, 
but improved longer-term renal function and survival. The focus 
of the renal protection has been on attenuation of the initial renal 
inflammatory response. The observed beneficial renal effects 3–4 
weeks following enrolment may suggest that recAP might also 
play a role in the modulation of inflammation-mediated repair 
mechanisms in the kidney. We advocate that future mechanistic 
studies focus on this putative mechanism of action.
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